Introduction
============

Baicalin (BA) is a major flavonoid constituent (Figure [1](#F1){ref-type="fig"}) found in the traditional Chinese medicinal herb Baikal skullcap (*Scutellaria baicalensis* Georgi), known as "Huang qin" in China and "Ogon" in Japan, which has been widely used for the treatment of various diseases such as pneumonia, hepatitis, and diarrhea (Huang et al., [@B10]). Previous studies have demonstrated that BA possesses a wide range of pharmacological and biological activities such as anti-inflammatory, anti-allergic, antimicrobial, antioxidant, and anti-tumor properties (Zhang et al., [@B26]). Its anti-inflammatory activity has been estimated in various animal models of acute and chronic inflammation (Kubo et al., [@B15]; Lin and Shieh, [@B17]; Zeng et al., [@B24]). Evidence shows that its anti-inflammatory actions are associated with the suppression of functions of various inflammatory cells and inhibition the production of pro-inflammatory mediators such as TNF-α, interleukin (IL)-1, and PGE~2~ (Chung et al., [@B5]; Krakauer et al., [@B14]). Recently, it is reported that BA can inhibit the proliferation of mouse T-lymphocytes stimulated with various mitogens and arrest lymphocytes in G~0~/G~1~ phase (Li et al., [@B16]). The results of these studies indicate that BA may have pronounced immunoregulatory properties, although the underlying mechanisms still remain to be fully elucidated.

![**The chemical structure of BA**.](fphar-02-00015-g001){#F1}

Dendritic cells (DCs) are potent antigen-presenting cells that initiate lymphocyte activation (Banchereau and Steinman, [@B2]; Banchereau et al., [@B1]). They develop from BM precursors and then migrate via the bloodstream to almost every tissue, where they reside as immature DCs. During pathogen invasion, or after exposure to inflammatory mediators, DCs undergo phenotypic and functional maturation, a state characterized by the up-regulation of class II major histocompatibility complex (MHC II) and costimulatory molecules (CD80/CD86) and the production of cytokines such as IL-12. Upon maturation, DCs in tissues migrate into afferent lymphatics and move to the T cell areas of lymph nodes, where they encounter naive T cells and initiate adaptive immune responses (Butcher and Picker, [@B3]). The apoptosis of DCs, upon completion of their task of antigen presentation, appears to serve as a negative immunoregulatory mechanism that may be crucial in controlling the magnitude of immune reactions against a given antigen (Hildeman et al., [@B9]). It has been demonstrated that elimination of DCs in experimental animals leads to immunologic ignorance or even paralysis of antigen-specific T cells after antigen exposure (Jung et al., [@B12]). Accordingly, the induction of premature DC death by immunomodulatory drugs appears to be a major pharmacologic principle of anti-inflammatory treatments (Hackstein and Thomson, [@B8]). In contrast, defects in DC apoptosis lead to DC accumulation, and through chronic lymphocyte activation, the development of autoimmunity (Chen et al., [@B4]).

The anti-inflammation effects of BA have been well-established and accumulated evidence indicates that BA may have potential immunomodulatory properties (Kubo et al., [@B15]; Chung et al., [@B5]; Lin and Shieh, [@B17]; Krakauer et al., [@B14]; Zhang et al., [@B26]; Zeng et al., [@B24]; Li et al., [@B16]). However, it effects on DCs have not been addressed. In this study, we used murine BM-derived DCs (BMDCs) to analyze its direct effects on DCs.

Materials and Methods
=====================

Reagents
--------

Baicalin (purity \>99%) was purchased from National Institute for the Control of Pharmaceutical and Biological Products, China. Lipopolysaccharide (LPS) and RPMI-1640 were purchased from Sigma (St Louis, MO, USA). Fetal calf serum was purchased from GIBCO-BRL (Gland Island, NY, USA). Recombinant mouse granulocyte--macrophage colony-stimulating factor (GM-CSF) and IL-4 were purchased from R&D System (Minneapolis, MN, USA). Fluorescein-5-isothiocyanate (FITC)-anti-mouse CD11c, PE-anti-mouse CD80, PE-Cy5-anti-mouse CD86, and anti-murine Fc receptor monoclonal antibodies were purchased from PharMingen (San Diego, CA, USA). The J-aggregate forming lipophilic cation 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbocyanine iodide (JC-1) was purchased from Molecular Probes (Eugene, OR, USA). Annexin V-FITC Apoptosis Detection kit was purchased from Keygen Biotech. Co., Ltd (Nanjing, China). All other chemicals used were of the highest grade available commercially.

Culture of bone marrow-derived DCs
----------------------------------

Bone marrow-derived DCs were generated according to the method described previously (Inaba et al., [@B11]) with some modification. In brief, BM cells were flushed from the femurs and tibiae of female C57BL/6 mice (purchased from Shanghai SLAC Laboratory Animal Co., Ltd, Shanghai, China), filtered through a Falcon 100-μm nylon cell strainer (BD Labware), and depleted of red blood cells by 5 min incubation in ACK lysis buffer (0.15 M NH~4~Cl, 1.0 mM KHCO~3~, 0.1 mM Na~2~EDTA, pH 7.4). Whole BM cells were plated in six-well plates (BD Labware) in RPMI-1640 supplemented with 10% FCS, GM-CSF (10 ng/ml), and IL-4 (10 ng/ml), and incubated at 37°C and 5% CO~2~. Three days later, the floating cells (mostly granulocytes) were removed, and the adherent cells were replenished with fresh medium containing GM-CSF and IL-4. Non-adherent and loosely adherent cells were harvested on day 6 as immature DC (typically contained \>90% cells expressing CD11c and MHC II on the surface, as determined by flow cytometry). To stimulate DCs maturation, LPS (500 ng/ml) was added to the culture on day 5 as indicated. For analysis of BA effects on DC development, BA (2--50 μM) was added on day 3.

Phenotypic marker analysis
--------------------------

Dendritic cells harvested on day 6 were washed and suspended in fluorescence-activated cell-sorting analysis (FACS) Buffer (phosphate buffered saline containing 0.1% bovine serum albumin and 0.01% NaN~3~), and stained with the fluorescence-conjugated monoclonal antibodies recognizing CD11c, CD80, or CD86 in the presence of anti-murine Fc receptor monoclonal antibody as described previously (Zhang et al., [@B25]). Samples were analyzed by flow cytometry on a FACSCalibur (Becton Dickinson, USA) with the CellQuest software package.

IL-12 assay
-----------

Interleukin-12 levels in the supernatants of BMDCs were determined by ELISA kits (Bender MedSystems, Vienna, Austria), according to the manufacturer\'s instructions.

Detection of apoptosis
----------------------

The annexin V-FITC binding and propidium iodide (PI) staining assay were used to assess apoptosis of DCs as described previously (Koopman et al., [@B13]). 1 × 10^6^ cells were stained with the annexin V-FITC and PI provided with the Annexin V-FITC Apoptosis Detection kit (purchased from Keygen Biotech. Co., Ltd, Nanjing, China), according to the manufacturer\'s instructions. Stained cells were analyzed via a FACSCalibur and the CellQuest software (Becton Dickinson, USA). Annexin V positive cells were determined as apoptosis cells.

Assay for mitochondrial membrane potential
------------------------------------------

Mitochondrial membrane potential (Δψ~m~) was determined by flow cytometry using J-aggregate forming lipophilic cationic probe JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbocyanine iodide) following the manufacturer\'s protocol (Molecular Probes, Eugene, OR, USA), and as described previously (Cossarizza et al., [@B6]). In brief, JC-1 was dissolved in dimethyl sulfoxide (5 mg/ml), and 50 μl were added to 10 ml of medium. 5 × 10^5^ DCs were incubated with 2 ml of medium containing JC-1 for 15 min at 37°C and then washed twice with PBS. Cells were then resuspended in 0.5 ml of PBS and analyzed on a FACSCalibur (Becton Dickinson, USA) to detect green fluorescence at excitation/emission wavelengths of 485/530 nm and red fluorescence at excitation/emission wavelengths of 550/595 nm. Since JC-1 exhibits potential-dependent accumulation in mitochondria, indicated by a fluorescence emission shift from green (\~525 nm) to red (\~590 nm), mitochondrial depolarization is indicated by a decrease in the red-to-green fluorescence--intensity ratio.

Statistics
----------

All data were expressed as the mean values ± SD. Differences between groups were examined for statistical significance using the Student\'s *t*-test. A value of *p* \< 0.05 was considered statistically significant.

Results
=======

Effects of BA on DC maturation and apoptosis
--------------------------------------------

The effect of BA on DCs was initially investigated in BM cell cultured for 6 days with GM-CSF and IL-4, which generates mainly BMDCs. BA (0--50 μM) was added on day 3, and LPS (500 ng/ml) was added on day 5 to stimulate DC maturation. The surface expressions of CD11c, CD80, and CD86 on BA-treated and -untreated DCs were examined by flow cytometry, and levels of IL-12 in the supernatants were measured by ELISA. The results demonstrated that more than 90% of non-adherent and loosely adherent cells were CD11c^+^ cells, and LPS stimulation markedly up-regulated the expression of CD80 and CD86 within the CD11c^+^ population (Figures [2](#F2){ref-type="fig"}A,D) and induced substantial release of IL-12 to the culture supernatants (Figure [2](#F2){ref-type="fig"}C), suggesting most cells harvested on day 6 were DCs. BA inclusion showed no effects on the up-regulation of CD80/CD86 expression in response to the stimulation of LPS (Figures [2](#F2){ref-type="fig"}A,D), but resulted in a concentration-dependent reduction of total numbers of viable CD11c^+^ cells recovered on day 6 of culture (Figure [2](#F2){ref-type="fig"}B), and significantly suppressed the release of IL-12 to culture supernatants (Figure [2](#F2){ref-type="fig"}C). To examine whether BA reduced cell recovery by inducing cell death, apoptosis in the day-6 DCs was further assessed by FACS after annexin V/PI staining. A significant degree of apoptosis was detected in the BA-treated DC, as shown by an increased phosphatidyl exposure using annexin V-FITC (Figure [2](#F2){ref-type="fig"}E).

![**Effects of BA on bone marrow-derived DC (BMDC) maturation and apoptosis**. **(A)** Effects of BA on the up-regulation of CD80/CD86 expressions on day-6 BMDCs in response to LPS stimulation. **(B)** Effect of BA on numbers of viable CD11c^+^ cells recovered on day 6 of culture BM cells (expressed as percentages of total viable number of CD11c^+^ cells in non-treatment control). **(C)** Effect of BA on the release of IL-12 into supernatants. **(A--C)** Results were obtained from three independent experiments and presented as mean values (±SD). \**p* \< 0.05 vs. LPS alone control by Student\'s *t*-test. **(D)** Representative histograms showing CD80 and CD86 expression on day-6 BMDCs from three independent experiments. **(E)** The percentage of apoptosis in day-6 BMDCs determined by FACS, using annexin V/PI staining. The results are representative of three independent experiments.](fphar-02-00015-g002){#F2}

Comparison of BA-induced apoptosis in immature and mature DC
------------------------------------------------------------

We further compared BA-induced apoptosis in mature DCs and immature DCs. In this experiment, the day-6 DCs stimulated with LPS were used as mature DCs, because they highly expressed CD80/CD86 and secreted high level of IL-12. In comparison, the day-6 DCs without stimulation by LPS were used as immature DCs. Mature and immature DCs were treated with 50 μM of BA for different time (24--72 h) or with graded concentrations of BA (12.5--50 μM) for 48 h, then cellular apoptosis was assessed by FACS after annexin V/PI staining. BA-induced apoptosis in both mature and immature DCs in time- and dose-dependent way and immature DCs were more sensitive for BA-induced apoptosis than mature DC (Figures [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}).

![**Baicalin-induced apoptosis in immature and mature DCs in a time-dependent way**. Immature and mature DCs were treated with 50 μM of BA for different time (24--72 h), then cells were harvested and apoptosis was assayed by flow cytometry, using annexin V/PI staining. Representative results of three independent experiments were presented.](fphar-02-00015-g003){#F3}

![**Baicalin-induced apoptosis in immature and mature DCs in a dose-dependent way**. Immature and mature DCs were treated with BA (0--50 μM) for 48 h, then cells were harvested and the percentage of apoptosis was determined by flow cytometry, using annexin V/PI staining. Results were obtained from three independent experiments and presented as mean values (±SD). \**p* \< 0.05 vs. 0 control, ^\#^*p* \< 0.05 vs. mature DC control by Student\'s *t*-test.](fphar-02-00015-g004){#F4}

Effects of BA on mitochondrial membrane potential in DCs
--------------------------------------------------------

One of the early critical events in apoptosis is the loss/disruption of mitochondrial membrane potential (Δψ~m~) in the cells, which eventually causes the initiation and activation of apoptotic cascades. We sought to determine whether BA-treatment had any effect on the Δψ~m~ in DCs using JC-1 staining. Figure [5](#F5){ref-type="fig"} shows treatment of DCs with BA resulted in dose-dependent increase in the proportion of green fluorescence-positive cells (indicating loss of mitochondrial membrane potential) in both immature DCs and mature DCs, and higher proportion of green fluorescence-positive cells were detected in BA-treated immature DCs. These results confirm that BA induced the loss of Δψ~m~ in DCs, which is more profound in immature DCs than in mature DCs.

![**The impact of BA on mitochondrial transmembrane potential in immature and mature DC**. Immature and mature DCs were treated with BA (0--50 μM) for 6 h, stained with JC-1 dye probe, and analyzed by flow cytometry. Numbers in lower right quadrant indicate the percentage of cells that emit only green fluorescence which is attributed to depolarized mitochondrial membrane. Representative of three individual experiments with similar results are shown.](fphar-02-00015-g005){#F5}

Discussion
==========

This is the first study demonstrating that BA can evoke apoptosis in DCs. BA addition into cytokine-driven cultures of murine BM cells resulted in a reduced recovery of CD11c^+^ cells and less production of IL-12, but shown no effects on the up-regulation of CD80/CD86 expression in response to the stimulation of LPS, suggesting BA has no influence on DC maturation, but may induce DC apoptosis. The fact that BMDCs underwent strong apoptosis in the presence of BA in a time- and dose-dependent manner further confirmed its pro-apoptotic activity. Interestingly, immature DCs were found more sensitive for BA-induced apoptosis than mature DC. Concordantly, BA induced more profound change of Δψ~m~ in immature DCs than in mature DCs, suggesting BA promote apoptosis through mitochondria-mediated pathway in DCs. A recent study investigated the effects of BA on apoptotic changes in multiple organs of severe acute pancreatitis rats. The results indicated that the apoptosis indexes significantly increased in lymph nodes and spleen in BA-treated group (Tian et al., [@B21]). Therefore, BA-induced DC apoptosis and the importance *in vivo* warrant further investigation.

Apoptosis regulates many aspects of immunologic homeostasis, including initiation, magnitude, and termination of immune responses (Giovannetti et al., [@B7]). During an immune response, homeostasis is disturbed as DCs become activated and promote the clonal expansion of antigen-specific lymphocytes. Shortly after the peak of the response, controlled induction of apoptosis, of both DCs and lymphocytes, restores homeostasis. This process is critical to ensure protective immunity and avoid lymphoid neoplasia and autoimmunity (Hildeman et al., [@B9]). While decreased apoptosis can cause an overabundance of lymphocytes and possibly autoimmune reactions, enhanced apoptosis can result in lymphocyte depletion and immunosuppression, so that the possibility to interfere with regulatory mechanisms of apoptosis, aiming either to block or to enhance it at different time points, represents a promising approach for the development of new immunomodulatory therapies (Rashedi et al., [@B20]). Previous studies have demonstrated that BA can inhibit the proliferation of T-lymphocytes (Li et al., [@B16]) and induce apoptosis in Jurkat T cells (Ueda et al., [@B22]). Here, we provide evidence that DCs may also primary target of BA for immunomodulation.

Traditionally, the development of immunosuppressive drugs and understanding of their action has been focused on lymphocytes. Many classical immunosuppressive agents, such as cyclosporine A, rapamycin, dexamethasone, and 1,25(OH)2D3, were found to modulate immune responses by inhibiting lymphocyte proliferation or promoting their apoptosis. However, recent evidence indicates that these agents interfere with immune responses at the earliest stage, targeting key functions of DCs (Hackstein and Thomson, [@B8]). For example, 1,25(OH)2D3 inhibits the differentiation and maturation of human DCs, abrogates the capacity of mature DCs to secrete IL-12 upon activation, while strongly enhancing IL-10 production, and promotes DC apoptosis (Penna and Adorini, [@B19]). Rapamycin has also been reported to induce apoptosis specifically in DCs but not in monocytes/macrophages (Woltman et al., [@B23]). Dexamethasone selectively inhibits differentiation of cord blood stem cell derived-DC precursors into immature DCs and selectively induces apoptosis of developing DCs (Mainali and Tew, [@B18]). All of these studies clearly establish that DCs are one of primary targets of many immunosuppressive drugs.

Our data indicate that BA induces selective apoptosis in immature DCs possibly through mitochondria-mediated pathway, suggesting a novel mechanism of immunomodulation by BA which may account, at least in part, for the immunosuppressive effects observed in the animal models and in clinical settings. The fact that BA, next to the antiproliferative effect on T cells, selectively induces apoptosis in immature DCs suggests that BA may have potential applications as a supportive treatment for autoimmune-mediated diseases.
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